Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Greg Pontone, MD, Chief of Aging Behavioral and Cognitive Neurology at the University of Florida, joins the podcast to discuss the interplay between cognition and Parkinson disease, with a focus on how clinicians can better recognize and manage cognitive changes across the disease course. Pontone outlines the prevalence of early cognitive impairment, noting that a significant proportion of patients may present with subtle deficits at diagnosis, particularly in executive function and processing speed.

The conversation explores the impact of commonly used medications on cognition, including anticholinergics and benzodiazepines, and how clinicians can balance therapeutic benefit with cognitive risk. Pontone also reviews current treatment strategies, including cholinesterase inhibitors and memantine, while emphasizing the importance of nonpharmacologic approaches such as structured routines and cognitive training. Additional discussion highlights the evolving role of biomarkers, the overlap between Parkinson disease and Alzheimer pathology, and the need for earlier recognition, better patient education, and continued research to improve long-term cognitive outcomes in this population.

Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.

Episode Breakdown:

• 1:10 – Prevalence and early signs of cognitive impairment in Parkinson disease
• 2:30 – Medication-related cognitive effects and contributing drug classes
• 4:20 – Balancing therapeutic benefit vs cognitive risk in treatment decisions
• 6:05 – Current treatments for cognition, including pharmacologic and behavioral strategies
• 10:25 – Neurology News Network
• 13:00 – Role of biomarkers and Alzheimer overlap in Parkinson cognition
• 15:45 – Future priorities for advancing cognitive care and research in PD

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Clears Cala kIQ Plus for Essential Tremor and Parkinson Disease Hand Tremor
• FDA Issues Complete Response Letter for GTx-104 in Patients With Aneurysmal Subarachnoid Hemorrhage
• Satralizumab Meets Primary End Point in Phase 3 METEOROID Study in MOGAD

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Julie Kurek, MD, Associate Professor of Neurology at Augusta University/Wellstar-MCG, joins the podcast to provide a clinical breakdown of how neurologists can differentiate dyskinesia from tremor in patients with Parkinson disease and other movement disorders. Drawing from bedside experience, Kurek outlines the key phenomenologic differences between these movements, emphasizing the importance of rhythm, distribution, and overall movement quality in distinguishing the two.

The conversation also explores how timing in relation to levodopa dosing serves as a critical diagnostic anchor, including recognition of peak-dose and biphasic dyskinesias. Kurek discusses real-world challenges in identifying patient-specific patterns, the importance of clinician–patient communication, and common diagnostic pitfalls, particularly in younger-onset or atypical presentations. She also highlights the growing role of digital tools, including wearable sensors and adaptive deep brain stimulation, in improving longitudinal monitoring and refining diagnostic accuracy in movement disorders.

Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.

Episode Breakdown:

• 1:10 – Clinical features distinguishing tremor vs dyskinesia at bedside
• 3:50 – Role of medication timing and levodopa response patterns
• 9:00 – Identifying patient-specific patterns and symptom awareness challenges
• 13:20 – Neurology News Network
• 16:10 – Common diagnostic pitfalls in Parkinson disease and movement disorders
• 17:50 – Role of wearables, biomarkers, and adaptive DBS in differentiation

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts Ultragenyx's Resubmitted BLA for MPS IIIA Gene Therapy UX111
• Elecsys NfL Test Receives European Approval for Monitoring Neuroinflammation in Relapsing-Remitting Multiple Sclerosis
• FDA Clears Cala kIQ Plus for Essential Tremor and Parkinson Disease Hand Tremor

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Sarah Hoffmann, MD, PhD, senior neurologist at Charité – University Medicine Berlin, provides clinical insight into the evolving and often challenging landscape of seronegative generalized myasthenia gravis (gMG). Drawing from both clinical experience and research, Hoffmann discusses how seronegative MG is defined in the absence of detectable antibodies and why it represents a heterogeneous and often underrecognized subgroup of patients. The conversation explores key diagnostic challenges, particularly in patients with limb-predominant symptoms, where differentiation from other neuromuscular or functional disorders can be difficult. Hoffmann also reviews current treatment approaches, noting that while standard therapies mirror antibody-positive MG, access to targeted treatments remains limited. Additional discussion focuses on the barriers to advancing clinical trials in this population, the need for reliable biomarkers to better stratify patients, and the importance of continually reassessing diagnosis in nonresponders to avoid both undertreatment and overtreatment.

Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

Episode Breakdown:

• 1:15 – Defining seronegative MG and estimating prevalence within overall patient population
• 2:15 – Diagnostic challenges and distinguishing seronegative MG from mimics and functional disorders
• 5:35 – Role and limitations of antibody testing, electrophysiology, and pharmacologic response
• 6:50 – Neurology News Network
• 9:05 – Current treatment strategies and variability in access to targeted therapies
• 11:55 – Barriers to clinical trials and need for improved patient stratification methods
• 13:05 – Key unanswered questions including biomarkers and reassessing diagnosis in nonresponders

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts Zilganersen New Drug Application for Priority Review in Alexander Disease
• FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome
• FDA Approves Higher Strength, More Effective Nusinersen Dose for Spinal Muscular Atrophy